International Biotechnology Trust : AGM Results 2023
December 20, 2023 at 06:10 am EST
Share
Annual General Meeting
International Biotechnology Trust plc (the "Company") announces that a poll was held on each of the resolutions proposed at the Annual General Meeting on 12 December 2023. The results of the poll are as follows:
Resolution
Votes for
%
Votes
%
Withheld
Total
(including
against
Votes
discretionary
Cast
votes)
(excludes
Votes
Withheld)
1
To receive the Annual
13,176,707
99.59%
54,014
0.41%
29,079
13,230,721
Report & Accounts
2
To approve Directors'
13,140,395
99.57%
57,300
0.43%
52,105
13,197,695
Remuneration report
3
To approve Directors'
13,124,663
99.45%
73,076
0.55%
52,061
13,197,739
Remuneration Policy
4
To approve the
13,221,854
99.96%
5,285
0.04%
32,661
13,227,139
Company's dividend
policy
5
To elect
13,183,660
99.81%
24,975
0.19%
41,165
13,208,635
Ms Gillian Elcock
6
To re-elect
13,186,241
99.81%
24,488
0.19%
39,071
13,210,729
Miss Kate Cornish-
Bowden
7
To re-elect Mrs Caroline
13,183,999
99.79%
28,180
0.21%
37,621
13,212,179
Gulliver
8
To re-elect Mr Patrick
13,183,935
99.87%
17,526
0.13%
48,339
13,201,461
Magee
9
To re-elect Professor
13,194,677
99.87%
17,502
0.13%
37,621
13,212,179
Patrick Maxwell
10
To re-appoint
13,163,331
99.66%
44,749
0.34%
41,720
13,208,080
PricewaterhouseCoopers
LLP as auditor
11
To authorise Directors'
13,205,377
99.86%
18,705
0.14%
35,718
13,224,082
determination of the
auditor's remuneration
12
To approve continuation
13,238,333
99.94%
7,585
0.06%
3,882
13,245,918
of the Company
13
To renew the authority
13,198,156
99.87%
16,797
0.13%
34,847
13,214,953
to allot shares
14
To renew the authority
13,190,925
99.84%
20,952
0.16%
37,923
13,211,877
to allot additional shares
15*
To approve the
13,149,544
99.53%
61,623
0.47%
38,633
13,211,167
disapplication of pre-
emption rights
16*
To approve the
12,825,508
96.87%
414,004
3.13%
10,288
13,239,512
disapplication of pre-
emption rights for
allotments of additional
shares
17*
To renew the authority
13,211,282
99.89%
14,275
0.11%
34,243
13,225,557
to purchase own shares
18*
To approve that a
13,156,468
99.57%
57,054
0.43%
36,278
13,213,522
general meeting, other
than an annual general
meeting, may be called
on not less than 14 clear
days' notice
*Resolution 15 to 18 were passed as special resolutions.
Shareholders are entitled to one vote per share. Votes withheld are not a vote in law and are therefore not counted in the calculation of the percentages of the votes cast for and against a resolution. Where shareholders appointed the Chairman as their proxy with discretion as to voting, their votes were cast in favour of the resolutions and their shares have been included in the "votes for" column.
The total issued share capital consists of 41,383,817 ordinary shares of £0.25 each, which includes 2,500,210 ordinary shares held in treasury. Treasury shares do not carry voting rights, therefore the total number voting rights in the Company is 38,883,607.
In accordance with LR 9.6.2, a copy of the resolutions passed, other than resolutions concerning ordinary business, at today's AGM will be submitted to the National Storage Mechanism and will be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
Attachments
Original Link
Original Document
Permalink
Disclaimer
International Biotechnology Trust plc published this content on 20 December 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 December 2023 11:09:35 UTC.
International Biotechnology Trust plc is a United Kingdom-based investment trust company. The Company's investment objective is to achieve long-term capital growth by investing in biotechnology and other life sciences companies addressing an unmet medical need. The Company seeks to achieve its objective by investing in a diversified portfolio of companies which may be quoted or unquoted and whose shares are considered to have growth prospects, with experienced management and strong potential upside through the development and/or commercialization of a pharmaceutical product, device or enabling technology. The Companyâs investments may also be made in related sectors, such as medical devices and healthcare services. The Company may invest through equities, index-linked securities and debt securities, cash deposits, money market instruments and foreign currency exchange transactions. SV Health Managers LLP is the Company's alternative investment fund manager (AIFM).